A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North central cancer treatment group study N0326

Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild, Alex A. Adjei

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North central cancer treatment group study N0326'. Together they form a unique fingerprint.

Medicine & Life Sciences